Evidence map›Paper›PMID 34954239›Full record

ArticlePreventive medicine2022

Short-term impact of the COVID-19 pandemic on a population-based screening program for colorectal cancer in Catalonia (Spain).

Nuria Vives, Gemma Binefa, Carmen Vidal, Núria Milà, Rafael Muñoz, Virtudes Guardiola, Olga Rial, Montse Garcia

Open access · greenAbstract read
In one paragraph

Article in Preventive medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.0field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Observational
  7. Article
  8. Article
  9. Observational
  10. Article
  11. Article
  12. Article
  13. Review
  14. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Nuria VivesCancer Screening Unit, Catalan Institute of Oncology, L'Hospitalet de Llobregat, Barcelona, Spain; Early Detection of Cancer Research Group, EPIBELL Programme, Bellvitge Biomedical Research Institute, L'Hospitalet de Llobregat, Barcelona, Spain.
Gemma BinefaCancer Screening Unit, Catalan Institute of Oncology, L'Hospitalet de Llobregat, Barcelona, Spain; Early Detection of Cancer Research Group, EPIBELL Programme, Bellvitge Biomedical Research Institute, L'Hospitalet de Llobregat, Barcelona, Spain; Consortium for Biomedical Research in Epidemiology and Public Health (CIBEResp), Madrid, Spain.
Carmen VidalCancer Screening Unit, Catalan Institute of Oncology, L'Hospitalet de Llobregat, Barcelona, Spain; Early Detection of Cancer Research Group, EPIBELL Programme, Bellvitge Biomedical Research Institute, L'Hospitalet de Llobregat, Barcelona, Spain; Consortium for Biomedical Research in Epidemiology and Public Health (CIBEResp), Madrid, Spain.
Núria MilàCancer Screening Unit, Catalan Institute of Oncology, L'Hospitalet de Llobregat, Barcelona, Spain; Early Detection of Cancer Research Group, EPIBELL Programme, Bellvitge Biomedical Research Institute, L'Hospitalet de Llobregat, Barcelona, Spain; Consortium for Biomedical Research in Epidemiology and Public Health (CIBEResp), Madrid, Spain.
Rafael MuñozCancer Screening Unit, Catalan Institute of Oncology, L'Hospitalet de Llobregat, Barcelona, Spain; Early Detection of Cancer Research Group, EPIBELL Programme, Bellvitge Biomedical Research Institute, L'Hospitalet de Llobregat, Barcelona, Spain.
Virtudes GuardiolaCancer Screening Unit, Catalan Institute of Oncology, L'Hospitalet de Llobregat, Barcelona, Spain; Early Detection of Cancer Research Group, EPIBELL Programme, Bellvitge Biomedical Research Institute, L'Hospitalet de Llobregat, Barcelona, Spain.
Olga RialCancer Screening Unit, Catalan Institute of Oncology, L'Hospitalet de Llobregat, Barcelona, Spain; Early Detection of Cancer Research Group, EPIBELL Programme, Bellvitge Biomedical Research Institute, L'Hospitalet de Llobregat, Barcelona, Spain.
Montse GarciaCancer Screening Unit, Catalan Institute of Oncology, L'Hospitalet de Llobregat, Barcelona, Spain; Early Detection of Cancer Research Group, EPIBELL Programme, Bellvitge Biomedical Research Institute, L'Hospitalet de Llobregat, Barcelona, Spain; Consortium for Biomedical Research in Epidemiology and Public Health (CIBEResp), Madrid, Spain. Electronic address: mgarcia@iconcologia.net.
Institut d'Investigació Biomédica de Bellvitge · ESCentro de Investigación Biomédica en Red de Epidemiología y Salud Pública · ESBellvitge University Hospital · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The COVID-19 pandemic caused the suspension at all levels of the Catalan FIT-based CRC screening program on March 12, 2020. Screening invitations to FIT were resumed on September 1, 2020. We aimed to assess the short-term impact of the pandemic and describe strategies implemented to minimize harm by the disruption of the FIT-based CRC screening in the Metropolitan Area of Barcelona. We analyzed participation rate, colonoscopy adherence, time intervals to colonoscopy, detection rates, and advanced-stage cancers in 2019 and 2020. To identify perceived distress levels during the suspension of the screening we conducted a phone interview. As a result of the suspension, 43% of the individuals due for screening did not receive their invitation by December 31, 2020. A percent decrease of 5.1% in participation and of 8.9% in colonoscopy adherence among invitees between January-March was observed, with a recovery to 2019 levels when the screening activities were restarted. The time interval between a positive test to colonoscopy was longer in 2020 than in 2019. A decrease in advanced neoplasia rate and an increase in later stages of CRC were also observed. Individuals with a positive test did not report higher levels of perceived distress compared to those with a negative test. Although the disruption of screening had a temporary impact on participation and colonoscopy adherence, timing delay continues and a large backlog in the invitation of the target population remains. Thus, it is critical to implement strategies to minimize the long-term effects.

Indexed as

Colorectal NeoplasmsCOVID-19ColonoscopyEarly Detection of CancerHumansMass ScreeningOccult BloodPandemicsSARS-CoV-2SpainColonoscopyColorectal cancerCoronavirusCOVID-19Fecal immunochemical testScreening

Identifiers

PMID34954239
PMCPMC8730718
OpenAlexW4225881749

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.